Redesigning oral medicines for ease of use

For many people, taking medicine is simple: Swallow a tablet with water and move on. But for millions of patients, especially children and older adults, it is not that straightforward. Tablets can be hard to swallow, taste unpleasant, or difficult to administer accurately. The result? Missed doses, incorrect use, and ultimately – less effective treatment.

To address this issue, the pharmaceutical industry is rethinking how medicines are made and delivered. The result is the rise of patient-centric oral solid dosage (OSD) forms: more effective medicines designed for ease of use and comfort. What's making these possible, alongside novel ingredients and human ingenuity, is advanced manufacturing technology that helps pharmaceutical companies turn complex ideas into scalable, reliable products. That is where GEA comes in.

From “one-size-fits-all” to patient-centric design

Traditional OSD forms like tablets and capsules have long been the backbone of healthcare. They are stable, easy to manufacture and cost-effective; but not always designed with patient experience in mind. Today, pharmaceutical companies are rethinking this model. Instead of asking patients to adapt to established treatment formats, they are designing medicines that adapt to each patient’s needs and improve adherence.

For children, this includes smaller, easier-to-swallow medicines or more pleasant-tasting alternatives. For older patients, this could be fast-dissolving tablets that do not require water – or flexible dosing options that accommodate changing needs. These innovations only become possible when drug producers can precisely control how these medicines are developed, processed and delivered. It is here where cutting-edge facilities and equipment play a critical role.

Small formats, big impact: pellets and mini tablets

One of the most promising developments is the use of drug-loaded pellets and mini tablets. These tiny units – often just millimeters in size – are filled into capsules or sachets, providing a flexible alternative to large tablets. For young patients, this means medication can be sprinkled on food or tailored to the exact dose required. For elderly patients, smaller units are easier to swallow and lower the risk of choking.

Medicines that melt in the mouth

Orally disintegrating tablets (ODT) offer another patient-friendly design breakthrough. ODTs dissolve quickly on the tongue without the need for water. For patients who have difficulty swallowing – commonly children and older adults – this format removes the stress of taking medicine.

Creating a tablet that can withstand packaging and transport yet is delicate enough to disintegrate quickly requires precision engineering. GEA granulation, drying and compression expertise help manufacturers achieve this balance by combining strength with rapid disintegration and effective taste-masking.

Rethinking how medicines are taken

Some of the most innovative formats turn medicine-taking on its head. One example is medicated drinking straws. These contain coated pellets that dissolve as the patient drinks liquid through a straw. For children, this makes taking medicine a more natural – even fun – activity. For caregivers, it simplifies administration and reduces resistance. Similarly, orodispersible films (thin strips placed on the tongue) offer a discreet and portable option that dissolves in seconds. These are particularly useful for patients on the go or those who struggle with traditional formats.

GEA supports these innovations with technologies that ensure precise drying, consistent product quality at scale and the uniform distribution of active ingredients.

Chewable and confectionery-inspired formats

Patient-centric design also draws inspiration from outside the traditional pharmaceutical sector. Chewable medicines, like gums and gummies, are gaining attention due to their familiarity and ease of use. Although more common in vitamins and supplements, these formats are of increasing interest for other applications. They offer clear advantages in terms of taste and acceptability, which are key factors when it comes to adherence, especially for younger patients. However, they also present technical challenges, such as maintaining dose uniformity and ensuring a long shelf life. 
GEA helps manufacturers overcome these hurdles thanks to its mixing, drying and hygienic processing expertise.

GEA makes complex medicines more accessible

Behind each new therapy is a complex manufacturing process that requires efficiency, scalability and compliance with strict regulatory standards. GEA brings these elements together with integrated solutions ranging from granulation and drying to coating, containment, tableting and continuous manufacturing.

As the pharmaceutical industry develops more complex medicines, the challenge to deliver them in convenient formats increases. For medicines that do not dissolve easily in the stomach, for example, technologies like spray drying can help. This processing step means treatments that might otherwise require injections can be taken orally. For patients, this results in fewer hospital visits, less invasive treatments and greater independence.

GEA’s broad portfolio and deep experience enable pharmaceutical companies to move from concept to commercial production faster and with confidence. This means new and improved therapies reach those who need them more quickly.

Putting patients at the center

The shift to more patient-centric OSD therapies reflects a broader change in healthcare. It is the recognition that effectiveness depends on what a medicine does, as well as if patients can and will take it as prescribed. By enabling a wide range of innovative formats, from pellets and mini tablets to dissolving films and medicated straws, GEA helps pharmaceutical companies design medicines that align with patient lifestyles and needs. Because when medicines are easier to take, they are more likely taken correctly. And that simple change can make all the difference.